Lexicon Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

    NEXT STORY
    Kiniksa Reports Second Quarter 2020 Financial Results and Highlights Recent Pipeline and Corporate Activity
    PREV STORY
    Lexicon Pharmaceuticals Enters Into Agreement With TerSera Therapeutics for the Sale of XERMELO
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update

    Net Ocaliva® (obeticholic acid or OCA) 4Q16 sales of $13.4 million, full year 2016 ...

    author_avatar
    NASDAQ Market News

    MediWound Strengthens its NexoBrid European Presence with Additional Distribution Agreements

    author_avatar
    NASDAQ Market News

    Anti-infective Drugs Market Outlook 2019-2024 – Rise of Multi-drug Resistant Organisms Drive the Market

    author_avatar
    NASDAQ Market News